Development and external validation of nomograms predicting distant metastases and overall survival after neoadjuvant chemotherapy and surgery for patients with nonmetastatic osteosarcoma: A multi‐institutional study
Authors:
Open Access
Abstract
BACKGROUND: In this era of individualized cancer treatment, data that could be applied to predicting the survival of patients with osteosarcoma are still limited because of the rarity of the disease and the difficulty in accumulating a sufficient number of patients. Therefore, a multi‐institutional collaboration was implemented to develop and externally validate nomograms that would predict metastasis‐free survival (MFS) and overall survival (OAS) for patients with nonmetastatic osteosarcoma.METHODS: This study retrospectively examined 1070 patients treated with neoadjuvant chemotherapy and surgery for nonmetastatic osteosarcoma. Data from Japanese patients (n = 557) were used to develop multivariate nomograms based on Cox regression. Six clinical and pathologic variables were built into nomograms estimating the probability of MFS and OAS 3 and 5 years after diagnosis. The model was internally validated for discrimination and calibration with bootstrap resampling and was externally validated with an independent patient cohort from Korea (n = 513).RESULTS: A patient's age, tumor site, and histologic response were found to have a stronger influence on MFS and OAS in the model than sex, tumor size, or pathologic fracture. The nomograms and calibration plots based on these results well predicted the probability of MFS (concordance index, 0.631) and OAS (concordance index, 0.679). The concordance indices for external validation were 0.682 for MFS and 0.665 for OAS.CONCLUSIONS: The nomograms were externally validated and verified to be useful for the prediction of MFS and OAS and for the assessment of the postoperative prognosis. They can be used for counseling patients and for establishing appropriate surveillance strategies after surgery. Cancer 2015;121:3844–3852. © 2015 American Cancer Society.Keywords
Funding Information
- Grant-in-Aid for Scientific Research from the Ministry of Education and Science (B, no. 22390296)
- the National Cancer Center Research and Development Fund (23-A-10)
This publication has 37 references indexed in Scilit:
- Inhibitory effects of tamoxifen and doxorubicin, alone and in combination, on the proliferation of the MG63 human osteosarcoma cell lineOncology Letters, 2013
- Prognostic nomogram for predicting the 5-year probability of developing metastasis after neo-adjuvant chemotherapy and definitive surgery for AJCC stage II extremity osteosarcomaAnnals of Oncology, 2009
- Time Dependency of Prognostic Factors in Patients with Stage II OsteosarcomasClinical Orthopaedics and Related Research, 2007
- Management of high-grade bone sarcomas over two decades: The Norwegian Radium Hospital experienceActa Oncologica, 2006
- Messenger RNA Expression Levels of CXCR4 Correlate with Metastatic Behavior and Outcome in Patients with OsteosarcomaClinical Cancer Research, 2005
- High‐dose methotrexate pharmacokinetics and outcome of children and young adults with osteosarcomaCancer, 2004
- A Comparison Study of Staging Systems for Bone SarcomasClinical Orthopaedics and Related Research, 2003
- Presurgical Chemotherapy Compared With Immediate Surgery and Adjuvant Chemotherapy for Nonmetastatic Osteosarcoma: Pediatric Oncology Group Study POG-8651Journal of Clinical Oncology, 2003
- Pathologic fracture in osteosarcoma. Impact of chemotherapy on primary tumor and survivalCancer, 1987
- The Effect of Adjuvant Chemotherapy on Relapse-Free Survival in Patients with Osteosarcoma of the ExtremityNew England Journal of Medicine, 1986